{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:38:49Z","timestamp":1761057529141,"version":"3.40.4"},"reference-count":9,"publisher":"S. Karger AG","issue":"3-4","license":[{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Res Paediatr"],"published-print":{"date-parts":[[2001]]},"abstract":"<i>Objective:<\/i> To evaluate the efficacy of oral dehydroepiandrosterone sulfate (DHEAS) treatment for atrichia pubis in female adolescents. <i>Study Design:<\/i> Two XY female adolescents with 17-hydroxylase deficiency and 2 XX females with panhypopituitarism presenting with atrichia pubis were treated with a daily dosage of DHEAS 10\u00a0mg\/m<sup>2<\/sup> body surface in addition to their regular substitution therapy. The dosage was increased according to clinical response. Pubic hair stages, growth and serum DHEAS were evaluated and in 1 case also serum IGFs and IGFBPs. <i>Results:<\/i> A dosage of 10 mg\/m<sup>2<\/sup> for 1 year led to serum DHEAS levels at the lower limit of the normal range. 15 mg\/m<sup>2<\/sup> was needed to achieve pubic hair stage 4\u20135 and axillary hair in patients with 17-hydroxylase deficiency. In panhypopituitarism, pubic hair developed at a slower pace and reached stage 4 on a dosage of 25\u2013 30 mg\/m<sup>2<\/sup>. Baseline serum IGF-I SDS was \u20130.67 and did not change on the initial dosage of DHEAS, in combination with submaximal estrogen substitution (10 \u00b5g ethinyl estradiol). On the combination of 15 mg\/m<sup>2<\/sup> DHEAS and full estrogen substitution, IGF-I SDS increased to an average of \u20130.15. IGFBP-3 SDS increased from 1.4 to a mean of 2.6 in the first year, and went back to 1.4 in the second year. IGFBP-6 SDS was low at baseline (\u20132.5) and rose to \u20131.9 and \u20131.7 IGF-II and IGFBP-1 showed an irregular pattern. <i>Conclusions:<\/i> Oral administration of DHEAS in a dosage of 15 mg\/m<sup>2<\/sup> o.d. is an efficacious treatment for atrichia pubis. For females with a panhypopituitarism a higher dosage appears needed. Given this and other biological actions of DHEAS, substitution therapy with DHEAS or DHEA to females with adrenal androgen deficiency appears rational.<\/jats:p>","DOI":"10.1159\/000048106","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T13:07:10Z","timestamp":1050412030000},"page":"134-139","source":"Crossref","is-referenced-by-count":1,"title":["Dehydroepiandrosterone Sulfate Treatment for Atrichia pubis"],"prefix":"10.1159","volume":"56","author":[{"given":"Jan-Maarten","family":"Wit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veerle J.","family":"Langenhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilma","family":"Oostdijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaap","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2002,2,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.78.6.1360"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92587-9"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.9.3147"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909303411401"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1159\/000023268"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.8.2578"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1210\/er.21.4.363"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/1043-2760(94)90114-7"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1998.00507.x"}],"container-title":["Hormone Research in Paediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/48106","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/48106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:00:02Z","timestamp":1745467202000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000048106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001]]},"references-count":9,"journal-issue":{"issue":"3-4","published-online":{"date-parts":[[2001,7,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000048106","archive":["Portico"],"relation":{},"ISSN":["1663-2818","1663-2826"],"issn-type":[{"type":"print","value":"1663-2818"},{"type":"electronic","value":"1663-2826"}],"subject":[],"published":{"date-parts":[[2001]]}}}